[go: up one dir, main page]

CY1110176T1 - Συνδυασμοι για θεραπεια hcv - Google Patents

Συνδυασμοι για θεραπεια hcv

Info

Publication number
CY1110176T1
CY1110176T1 CY20091100274T CY091100274T CY1110176T1 CY 1110176 T1 CY1110176 T1 CY 1110176T1 CY 20091100274 T CY20091100274 T CY 20091100274T CY 091100274 T CY091100274 T CY 091100274T CY 1110176 T1 CY1110176 T1 CY 1110176T1
Authority
CY
Cyprus
Prior art keywords
hepatitis
relates
combinations
virus
combination
Prior art date
Application number
CY20091100274T
Other languages
English (en)
Inventor
Roger D Tung
Gurudatt Chandorkar
Robert B Perni
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of CY1110176T1 publication Critical patent/CY1110176T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Catalysts (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση αφορά την συν-χορήγηση ενός αναστολέα πρωτεάσης NS3/4A ιού Ηπατίτιδας C και ενός αναστολέα μονο-οξυγενάσης κυτοχρώματος Ρ450. Ο συνδυασμός δρα αλληλεπιδρώντας με τον κύκλο ζωής του ιού ηπατίτιδας C και επομένως είναι χρήσιμος ως μια αντι-ιϊκή θεραπεία. Έτσι, ο συνδυασμός μπορεί να χρησιμοποιείται για την θεραπεία ή πρόληψη μολύνσεων ηπατίτιδας C σε ασθενείς. Η εφεύρεση επίσης αφορά συνθέσεις που περιλαμβάνουν τον συνδυασμό αναστολέων. Η εφεύρεση επίσης αφορά κιτ και φαρμακευτικές συσκευασίες που περιλαμβάνουν έναν αναστολέα πρωτεάσης NS3/4A ιού ηπατίτιδας C και ένα αναστολέα μονο-οξυγενάσης κυτοχρώματος Ρ450. Η εφεύρεση επίσης αφορά μεθόδους παρασκευής αυτών των συνθέσεων, συνδυασμών, κιτ και συσκευασιών.
CY20091100274T 2003-10-27 2009-03-10 Συνδυασμοι για θεραπεια hcv CY1110176T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51485303P 2003-10-27 2003-10-27
EP04810032A EP1677827B1 (en) 2003-10-27 2004-10-27 Combinations for hcv treatment

Publications (1)

Publication Number Publication Date
CY1110176T1 true CY1110176T1 (el) 2015-01-14

Family

ID=34549356

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100274T CY1110176T1 (el) 2003-10-27 2009-03-10 Συνδυασμοι για θεραπεια hcv

Country Status (22)

Country Link
US (3) US20060003942A1 (el)
EP (1) EP1677827B1 (el)
JP (1) JP2007509950A (el)
KR (1) KR20060120162A (el)
CN (1) CN1893978A (el)
AT (1) ATE416789T1 (el)
AU (1) AU2004285503A1 (el)
BR (1) BRPI0415935A (el)
CA (1) CA2543696A1 (el)
CY (1) CY1110176T1 (el)
DE (1) DE602004018363D1 (el)
DK (1) DK1677827T3 (el)
ES (1) ES2319775T3 (el)
IL (1) IL175211A0 (el)
MX (1) MXPA06004723A (el)
NO (1) NO20062428L (el)
PL (1) PL1677827T3 (el)
PT (1) PT1677827E (el)
RU (1) RU2006118359A (el)
SI (1) SI1677827T1 (el)
WO (1) WO2005042020A2 (el)
ZA (1) ZA200603863B (el)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9712544B1 (pt) 1996-10-18 2013-10-22 Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
AR049297A1 (es) * 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
EP2256113A1 (en) * 2005-08-02 2010-12-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US8039475B2 (en) 2006-02-27 2011-10-18 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP5646814B2 (ja) * 2006-03-06 2014-12-24 アッヴィ・インコーポレイテッド Ｈｃｖを治療するためのリトナビルの組成物及び使用方法
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
WO2007109604A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
MX2008012225A (es) * 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
EP2007789B1 (en) * 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
WO2007149382A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in treating hepatitis
ES2796275T3 (es) 2006-07-07 2020-11-26 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
KR20090115970A (ko) * 2007-02-27 2009-11-10 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 그를 포함하는 제약 조성물
AU2008219704A1 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
JP5393665B2 (ja) * 2007-07-06 2014-01-22 ギリアード サイエンシーズ， インコーポレイテッド 治療剤の薬物動態特性の調整剤
ATE530546T1 (de) * 2007-08-30 2011-11-15 Vertex Pharma Kokristalle und pharmazeutische zusammensetzungen damit
US20090082366A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
MX2010003916A (es) 2007-10-10 2010-05-05 Novartis Ag Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih).
CN103585127A (zh) * 2008-02-28 2014-02-19 Abbvie公司 片剂和其制备方法
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
EP2393359A4 (en) * 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
US8314135B2 (en) * 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8242156B2 (en) * 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US9339531B2 (en) 2009-02-26 2016-05-17 The Johns Hopkins University Recognition of CYP2E1 epitopes
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CA2758484A1 (en) * 2009-04-15 2010-10-21 David A. Degoey Anti-viral compounds
RU2591830C2 (ru) * 2009-04-25 2016-07-20 Ф. Хоффманн-Ля Рош Аг Способы улучшения фармакокинетики
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
TWI402070B (zh) * 2009-06-11 2013-07-21 Abbott Lab 抗病毒化合物
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (en) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) * 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8653070B2 (en) * 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2787309A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8178531B2 (en) * 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
CN102858157A (zh) * 2010-03-04 2013-01-02 埃南塔制药公司 作为hcv复制的抑制剂的组合药物活性剂
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012021704A1 (en) * 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
KR20130120481A (ko) 2010-10-08 2013-11-04 노파르티스 아게 술파미드 ｎｓ3 억제제의 비타민 ｅ 제제
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
RU2013155713A (ru) 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
WO2013040492A2 (en) 2011-09-16 2013-03-21 Gilead Sciences, Inc. Methods for treating hcv
KR101621181B1 (ko) * 2011-10-10 2016-05-13 에프. 호프만-라 로슈 아게 항바이러스성 화합물
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
AU2013262416B2 (en) * 2012-05-18 2017-05-11 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
CA2876496A1 (en) * 2012-06-27 2014-01-03 Abbvie Inc. Methods for treating hcv
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP3317274A4 (en) 2015-06-30 2019-05-08 Eiger Group International, Inc. USE OF CHLOROQUIN AND CLEMIZOL COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY AND CANCER DISEASES
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3999101A1 (en) * 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CZ20033368A3 (en) * 2001-06-11 2004-04-14 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
EP1613620A1 (en) * 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW200523270A (en) * 2003-07-18 2005-07-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
TW200528472A (en) * 2003-10-10 2005-09-01 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c

Also Published As

Publication number Publication date
WO2005042020A3 (en) 2005-06-23
ZA200603863B (en) 2007-11-28
IL175211A0 (en) 2006-09-05
KR20060120162A (ko) 2006-11-24
RU2006118359A (ru) 2007-12-10
SI1677827T1 (sl) 2009-06-30
DE602004018363D1 (de) 2009-01-22
US20120114604A1 (en) 2012-05-10
ES2319775T3 (es) 2009-05-12
CA2543696A1 (en) 2005-05-12
NO20062428L (no) 2006-05-29
JP2007509950A (ja) 2007-04-19
ATE416789T1 (de) 2008-12-15
US20100015090A1 (en) 2010-01-21
WO2005042020A2 (en) 2005-05-12
PT1677827E (pt) 2009-03-13
US20060003942A1 (en) 2006-01-05
BRPI0415935A (pt) 2007-01-02
MXPA06004723A (es) 2006-07-05
EP1677827A2 (en) 2006-07-12
AU2004285503A1 (en) 2005-05-12
DK1677827T3 (da) 2009-03-30
PL1677827T3 (pl) 2009-06-30
EP1677827B1 (en) 2008-12-10
CN1893978A (zh) 2007-01-10

Similar Documents

Publication Publication Date Title
CY1110176T1 (el) Συνδυασμοι για θεραπεια hcv
PT1268519E (pt) Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
MY148123A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
BRPI0410456B8 (pt) compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
PL1987038T3 (pl) Inhibitory HCV NS5B
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
MX2009009176A (es) Inhibidores de serina-proteasas.
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
TW200740850A (en) HCV NS3 protease inhibitors
SG155967A1 (en) Hcv ns3-ns4a protease inhibition
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
TW200728317A (en) Macrocylic inhibitors of hepatitis C virus
UA95990C2 (en) Hcv ns3 protease inhibitors